Cannabidiol dimethyl ether: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
No edit summary |
||
| Line 21: | Line 21: | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] | ||
{{pharmacology-stub}} | {{pharmacology-stub}} | ||
<gallery> | <gallery> | ||
File:CBDD_structure.png | File:CBDD_structure.png | ||
File:CBDD_3D_BS.png | File:CBDD_3D_BS.png | ||
</gallery> | </gallery> | ||
Latest revision as of 19:31, 16 March 2025
Cannabidiol dimethyl ether (CBDDME) is a cannabinoid derivative that is structurally related to cannabidiol (CBD). It is a non-psychoactive compound, meaning it does not produce the "high" associated with tetrahydrocannabinol (THC).
Chemistry[edit]
CBDDME is a dimethyl ether derivative of cannabidiol. It is synthesized by replacing the phenolic hydroxyl groups in CBD with methoxy groups. This results in a compound with a similar structure to CBD, but with different chemical properties.
Pharmacology[edit]
Like CBD, CBDDME is believed to interact with the endocannabinoid system in the body. This system is involved in a variety of physiological processes, including pain sensation, mood, and memory. However, the exact mechanism of action of CBDDME is not fully understood.
Potential Therapeutic Uses[edit]
Research into the potential therapeutic uses of CBDDME is still in its early stages. However, preliminary studies suggest that it may have anti-inflammatory, analgesic, and neuroprotective effects. It may also have potential as a treatment for conditions such as epilepsy, chronic pain, and neurodegenerative diseases.
Legal Status[edit]
The legal status of CBDDME varies by country and is often tied to the legal status of cannabis and CBD. In some jurisdictions, it is classified as a controlled substance, while in others it is legal for medical or recreational use.
See Also[edit]
